GLP-1 drugs may reduce binge-eating symptoms, but evidence for treating diagnosed binge-eating disorder remains limited. Reports of less food noise during semaglutide treatment describe thoughts and preoccupation with food. Clinical trials can measure a different outcome, such as how often people have binge episodes.[1][2]
What the larger review found
The 2026 review included 25 randomized trials with 8,069 participants across several eating-related outcomes. Nine trials with 2,106 participants contributed to the binge-eating estimate. The standardized difference favored GLP-1 drugs (Hedges’ g −0.23, 95% CI −0.36 to −0.10). Because the measure combines different scales, it cannot tell you how many fewer binge episodes to expect.[1]
The studies also reported less loss of control over eating and more cognitive or dietary restraint. The review could not determine whether that added restraint was harmful. The authors found substantial differences across studies and called for longer, adequately powered trials in people with diagnosed binge-eating disorder.[1]
What a trial in diagnosed binge-eating disorder found
In a 17-week pilot trial, the analysis included 27 adults with binge-eating disorder. Weekly binge episodes decreased in both groups, and the difference between liraglutide and placebo was not statistically significant. The researchers identified a pharmacy dispensing error as a major limitation. The trial illustrates why changes in eating behavior and changes in body weight need to be measured separately.[3]